Neuropharmacological efficacy of metformin for stroke in rodents: A meta-analysis of preclinical trials.
Neuropharmacological efficacy of metformin for stroke in rodents: A meta-analysis of preclinical trials.
复制标题
二甲双胍治疗啮齿动物中风的神经药理学功效：临床前试验的荟萃分析
DOI：
10.3389/fphar.2022.1009169
复制
发表时间：
2022
影响因子：
5.6
通讯作者：
中科院分区：
文献类型：
--
作者：
背景资料：卒中，包括缺血性卒中、脑内出血和蛛网膜下腔出血（SAH），仍然是全球死亡的主要原因。不同的中风亚型在多个健康领域具有相似的有害影响。以往的研究表明，二甲双胍在实验性脑卒中动物模型中具有神经保护作用;然而，二甲双胍治疗脑卒中能力的临床前定量分析仍然缺乏。本荟萃分析评价了二甲双胍在改善啮齿动物卒中模型中卒中预后的疗效。 方法：从PubMed、EMBASE和Web of Science中检索相关临床前试验。使用标准化平均差（SMD）和相应的置信区间（CI）比较对照组和二甲双胍组之间的神经学评分（NS）、脑含水量（BWC）、梗死面积、旋转棒试验、TUNEL、神经元数量、小胶质细胞数量和p-AMPK水平。使用SYRCLE的偏倚风险工具评估质量。 结果：2010年至2022年发表的15篇文章被纳入荟萃分析。二甲双胍组与对照组相比在以下方面具有统计学显著性差异：NS（SMD −1.45; 95% CI −2.32，−0.58; p = 0.001），《生物武器公约》（SMD −3.22; 95% CI −4.69，−1.76; p < 0.0001），梗死面积（SMD −2.90; 95% CI −3.95，−1.85; p < 0.00001），旋转棒检验（SMD 2.55; 95% CI 1.87，3.23; p < 0.00001），TUNEL（SMD -3.63; 95% CI −5.77，−1.48; p = 0.0009），神经元数量（SMD 3.42; 95% CI 2.51，4.34; p < 0.00001），小胶质细胞数量（SMD −3.06; 95% CI-4.69，−1.44; p = 0.0002）和p-AMPK水平（SMD 2.92; 95% CI 2.02，3.82; p < 0.00001）。对异质性结局指标进行敏感性分析和分层分析。 结论：总体而言，二甲双胍治疗可改善卒中引发的严重结局。尽管动物研究存在固有的局限性，但本系统评价可能为未来高质量的临床前试验和临床使用提供重要参考。
Background: Stroke, including ischemic stroke, intracerebral hemorrhage, and subarachnoid hemorrhage (SAH), remains a leading cause of mortality globally. Different stroke subtypes have similar detrimental effects in multiple fields of health. Previous research has shown that metformin plays a neuroprotective role in experimental animal models of stroke; however, a preclinical quantitative analysis on the ability of metformin to treat stroke is still lacking. This meta-analysis evaluates the efficacy of metformin in improving stroke prognosis in rodent models of stroke. Methods: Relevant preclinical trials were retrieved from PubMed, EMBASE, and the Web of Science. The neurological score (NS), brain water content (BWC), infarct size, rotarod test, TUNEL, neuron quantity, microglia quantity, and p-AMPK levels were compared between a control group and a metformin group using the standardized mean difference (SMD) and corresponding confidence interval (CI). Quality was assessed with SYRCLE’s risk of bias tool. Results: Fifteen articles published from 2010 to 2022 were included in the meta-analysis. The metformin group had statistically significant differences compared to the control group in the following aspects: NS (SMD −1.45; 95% CI −2.32, −0.58; p = 0.001), BWC (SMD −3.22; 95% CI −4.69, −1.76; p < 0.0001), infarct size (SMD −2.90; 95% CI −3.95, −1.85; p < 0.00001), rotarod test (SMD 2.55; 95% CI 1.87, 3.23; p < 0.00001), TUNEL (SMD -3.63; 95% CI −5.77, −1.48; p = 0.0009), neuron quantity (SMD 3.42; 95% CI 2.51, 4.34; p < 0.00001), microglia quantity (SMD −3.06; 95% CI -4.69, −1.44; p = 0.0002), and p-AMPK levels (SMD 2.92; 95% CI 2.02, 3.82; p < 0.00001). Furthermore, sensitivity analysis and stratified analysis were conducted for heterogeneous outcome indicators. Conclusion: Overall, metformin treatment improves severe outcomes triggered by stroke. Despite the limitations intrinsic to animal studies, this systematic review may provide a vital reference for future high-quality preclinical trials and clinical use.
登录
查看更多内容
通过调节AMPK/CREB/BDNF途径，急性施用二甲双胍可预防脑缺血再灌注损伤引起的神经元凋亡。
影响因子：
5.6
作者：
Liu, Ke;Li, Lulu;Liu, Zhijun;Li, Gang;Wu, Yanqing;Jiang, Xingjun;Wang, Mengdie;Chang, Yanmin;Jiang, Tingting;Luo, Jianheng;Zhu, Jiahui;Li, Hongge;Wang, Yong
通讯作者：
Wang, Yong
影响因子：
13.8
作者：
Gu HQ;Yang X;Wang CJ;Zhao XQ;Wang YL;Liu LP;Meng X;Jiang Y;Li H;Liu C;Wangqin R;Fonarow GC;Schwamm LH;Xian Y;Li ZX;Wang YJ
通讯作者：
Wang YJ
影响因子：
5.5
作者：
Liu, Jiu-Hong;Feng, Dan;Pei, Lei
通讯作者：
Pei, Lei
DOI：
10.1016/j.jstrokecerebrovasdis.2013.09.001
发表时间：
2014-02-01
影响因子：
2.5
作者：
Cheng, Yuan-Yang;Leu, Hsin-Bang;Kao, Chung-Lan
通讯作者：
Kao, Chung-Lan
二甲双胍可减轻小鼠大脑中动脉闭塞后血脑屏障的破坏
影响因子：
9.3
作者：
Liu Y;Tang G;Li Y;Wang Y;Chen X;Gu X;Zhang Z;Wang Y;Yang GY
通讯作者：
Yang GY